Source: MedPage Today
By: Smith, Michael
The 13-valent pneumococcal conjugate vaccine significantly reduced the incidence of disease associated with the new bacterial types included, new research from the Centers for Disease Control and Prevention (CDC) suggests. The PCV13 vaccine was introduced in 2010, adding six pneumococcal serotypes that were not in the earlier PCV7 product. Among children under age two, the CDC estimates that the vaccine reduced disease incidence between 50 percent and 60 percent. Researchers studied data from 10 centers in the CDC’s Active Bacterial Core surveillance program, looking at five of the new pneumococcal serotypes included in the PCV13 vaccine. When the scientists compared the average disease incidence among children under age two years in the first quarters of the baseline years to the first quarter of 2012, they found that disease linked to the five new strains dropped 90 percent and disease caused by all serotypes declined by 55 percent. The CDC’s Matthew Moore presented the findings at the annual IDWeek meeting in San Diego.